Henan Cancer Hospital
Zhengzhou, Henan, China
184 recruiting
Showing 1–20 of 293 trials
Recruiting
Phase 1
A Study of BG-C477 in Participants With Advanced Solid Tumors
Advanced Solid Tumors
BeOne Medicines310 enrolled54 locationsNCT06596473
Recruiting
Phase 3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled257 locationsNCT06852222
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Acute Leukemia
Janssen Research & Development, LLC420 enrolled102 locationsNCT04811560
Recruiting
Phase 3
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.500 enrolled193 locationsNCT04892173
Recruiting
Phase 3
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital1,044 enrolled1 locationNCT07629817
Recruiting
Phase 1
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Relapsed/Refractory Hematological MalignanciesRelapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLLRelapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)+4 more
Ascentage Pharma Group Inc.180 enrolled6 locationsNCT07424833
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled404 locationsNCT05920356
Recruiting
Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled237 locationsNCT06629779
Recruiting
Phase 1Phase 2
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Hematologic Malignancies
Sellas Life Sciences Group160 enrolled26 locationsNCT04588922
Recruiting
Phase 2
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
BioNTech SE105 enrolled24 locationsNCT07255404
Recruiting
Phase 1Phase 2
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Hepatocellular Carcinoma
Lepu Biopharma Co., Ltd.160 enrolled8 locationsNCT07479485
Recruiting
Phase 2
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital120 enrolled7 locationsNCT07733830
Recruiting
Phase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Colorectal, CancerPancreatic CancerGastric Cancer+1 more
ArriVent BioPharma, Inc.572 enrolled21 locationsNCT07066657
Recruiting
Phase 3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Non-small Cell Lung Cancer
Boehringer Ingelheim400 enrolled199 locationsNCT07195695
Recruiting
Phase 3
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
Extensive-stage Small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.562 enrolled2 locationsNCT07502300
Recruiting
Phase 3
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Shanghai Junshi Bioscience Co., Ltd.756 enrolled76 locationsNCT06095583
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled84 locationsNCT04973605
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.75 enrolled29 locationsNCT07082686
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled127 locationsNCT05006716
Recruiting
Phase 3
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines500 enrolled197 locationsNCT06973187